MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

NEXT STORY
NasoNeb Welcomes Leading Otolaryngologists to Medical Advisory Board
PREV STORY
Trauma & Extremities Devices Market Research Report by Device, by Injury, by End User, by State – United States Forecast to 2025 – Cumulative Impact of COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

author_avatar
NASDAQ Market News

Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

author_avatar
NASDAQ Market News

Curetis Provides Business Update for the First Nine Months of 2019

author_avatar
NASDAQ Market News